Ovid Therapeutics Inc. (OVID) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
OVID Revenue Growth
Revenue Breakdown (FY 2025)
OVID's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
OVID Revenue Analysis (2014–2025)
As of May 8, 2026, Ovid Therapeutics Inc. (OVID) generated trailing twelve-month (TTM) revenue of $7.3 million, reflecting explosive growth of +844.7% year-over-year. The most recent quarter (Q4 2025) recorded $718,000 in revenue, up 443.9% sequentially.
Looking at the longer-term picture, OVID's 5-year compound annual growth rate (CAGR) stands at -10.5%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $208.4 million in 2021.
Revenue diversification analysis shows OVID's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), LGND (+64.8% YoY), and RARE (+13.3% YoY), OVID has outperformed the peer group in terms of revenue growth. Compare OVID vs ACAD →
OVID Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| OVIDCurrent | $7M | +844.7% | -10.5% | -585.2% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 LGND | $167M | +64.8% | +6.8% | -13.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
OVID Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.3M | +1181.3% | $7.0M | 95.9% | $-42,439,000 | -585.2% |
| 2024 | $566K | +44.4% | $566K | 100.0% | $-61,885,000 | -10933.7% |
| 2023 | $392K | -73.9% | $392K | 100.0% | $-59,281,000 | -15122.7% |
| 2022 | $1.5M | -99.3% | $1.5M | 100.0% | $-55,548,161 | -3696.4% |
| 2021 | $208.4M | +1551.6% | $208.4M | 100.0% | $124.2M | 59.6% |
| 2020 | $12.6M | - | $12.6M | 100.0% | $-81,430,977 | -645.4% |
| 2019 | $0 | - | $0 | - | $-61,409,467 | - |
| 2018 | $0 | - | $-142,000 | - | $-52,932,000 | - |
| 2017 | $0 | - | $-80,310 | - | $-65,008,000 | - |
| 2016 | $0 | - | $-56,512 | - | $-22,535,000 | - |
See OVID's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OVID Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OVID vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOVID — Frequently Asked Questions
Quick answers to the most common questions about buying OVID stock.
Is OVID's revenue growth accelerating or slowing?
OVID revenue is accelerating at +844.7% year-over-year, exceeding the 5-year CAGR of -10.5%. TTM revenue reached $7M. Growth momentum has increased versus prior periods.
What is OVID's long-term revenue growth rate?
Ovid Therapeutics Inc.'s 5-year revenue CAGR of -10.5% reflects the sustained expansion pattern. Current YoY growth of +844.7% is above this long-term average.
How is OVID's revenue distributed by segment?
OVID reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.